Thalidomide treatment reduces apoptosis levels in bone marrow cells from patients with myelodysplastic syndromes

Leukemia Research

Volumn 29, Issue 6, 2005, Pages 641-647

  Invernizzi, Rosangela ^a   Travaglino, Erica ^a   De Amici, Mara ^a   Brugnatelli, Silvia ^a   Ramajoli, Isabella ^a   Rovati, Bianca ^a   Benatti, Chiara ^a   Ascari, Edoardo ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Angiogenic cytokines; Apoptosis; Lymphocyte subsets; Matrix metalloproteinases; Myelodysplastic syndromes; Thalidomide

Indexed keywords

FIBROBLAST GROWTH FACTOR; GELATINASE A; GELATINASE B; INTERLEUKIN 1BETA; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ADULT; AGED; APOPTOSIS; ARTICLE; BLOOD; BONE MARROW CELL; CELL PROLIFERATION; CLINICAL ARTICLE; CONSTIPATION; DROWSINESS; DRUG ERUPTION; FATIGUE; FEMALE; HUMAN; INHIBITION KINETICS; LYMPHOCYTE; MALE; MYELODYSPLASTIC SYNDROME; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RASH; SOMNOLENCE; STATISTICAL SIGNIFICANCE; THROMBOCYTOPENIA; TRANSFUSION; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 18044393194     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2004.11.008     Document Type: Article

References (25)

1. G. Pruneri, F. Bertolini, D. Soligo, N. Carboni, A. Cortelezzi, and P.F. Ferrucci Angiogenesis in myelodysplastic syndromes Br J Cancer 81 1999 1398 1401
2. A. Aguayo, H. Kantarjian, T. Manshouri, C. Gidel, E. Estey, and D. Thomas Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes Blood 96 2000 2240 2245
3. M.H. Mangi, and A.C. Newland Angiogenesis and angiogenic mediators in haematological malignancies Br J Haematol 111 2000 43 51
4. A. Raza, P. Meyer, D. Dutt, F. Zorat, L. Lisak, and F. Nascimben Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes Blood 98 2001 958 965
5. F. Zorat, V. Shetty, D. Dutt, L. Lisak, F. Nascimben, and K. Allampallam The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes Br J Haematol 115 2001 881 894
6. P. Musto, A. Falcone, G. Sanpaolo, M. Bisceglia, R. Matera, and A.M. Carella Thalidomide abolishes transfusion-dependence in selected patients with myelodysplastic syndromes Haematologica 87 2002 884 886
7. C. Strupp, U. Germing, M. Aivado, E. Misgeld, R. Haas, and N. Gattermann Thalidomide for the treatment of patients with myelodysplastic syndromes Leukemia 16 2002 1 6
8. C. Strupp, B. Hildebrandt, U. Germing, R. Haas, and N. Gattermann Cytogenetic response to thalidomide treatment in three patients with myelodysplastic syndrome Leukemia 17 2003 1200 1202
9. G. Mufti, A.F. List, S.D. Gore, and A.Y. Ho Myelodysplastic syndrome Hematology (Am Soc Hematol Educ Program) 2003 176 199
10. P. Musto Thalidomide therapy for myelodysplastic syndromes: current status and future perspectives Leuk Res 28 2004 325 332
11. B.D. Cheson, J.M. Bennett, H. Kantarjian, A. Pinto, and C.A. Schiffer Report of an international working group to standardize response criteria for myelodysplastic syndromes Blood 96 2000 3671 3674
12. W.T. Bellamy, L. Richter, D. Sirjani, C. Roxas, B. Glinsmann-Gibson, and Y. Frutiger Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes Blood 97 2001 1427 1434
13. S. Verstovsek, E. Estey, T. Manshouri, F.J. Giles, J. Cortes, and M. Beran Clinical relevance of vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukaemia and myelodysplastic syndrome Br J Haematol 118 2002 151 156
14. J.D. Klausner, V.H. Freedman, and G. Kaplan Thalidomide as an anti-TNF-α inhibitor: implications for clinical use Clin Immunol Immunopathol 81 1996 219 223
15. P.A. Haslett, L.G. Corral, M. Albert, and G. Kaplan Thalidomide co-stimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset J Exp Med 187 1998 1885 1892
16. R.J. D'Amato, M.S. Loughnan, E. Flynn, and J. Folkman Thalidomide is an inhibitor of angiogenesis Proc Natl Acad Sci U S A 91 1999 4082 4085
17. S. Singhal, J. Mehta, R. Desikan, D. Ayers, P. Roberson, and P. Eddlemon Antitumor activity of thalidomide in refractory multiple myeloma N Engl J Med 341 1999 1565 1571
18. M. Marchetti, G. Barosi, F. Balestri, G. Viarengo, S. Gentili, and S. Barulli Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial J Clin Oncol 22 2004 424 431
19. M.B. Steins, T. Padrò, R. Bieker, S. Ruiz, M. Kropff, and J. Kienast Efficacy and safety of thalidomide in patients with acute myeloid leukemia Blood 99 2002 834 839
20. D.A. Thomas, E. Estey, F.J. Giles, S. Faderl, J. Cortes, and M. Keating Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemia Br J Haematol 123 2003 436 441
21. A.L. Moreira, D.R. Friedlander, B. Shif, G. Kaplan, and D. Zagzag Thalidomide and a thalidomide analogue inhibit endothelial cell proliferation in vitro J Neurooncol 43 1999 109 114
22. R. Invernizzi The role of apoptosis in myelodysplastic syndrome Haematologica 87 2002 337 339
23. J.J. Melenhorst, R. Eniafe, R. Follmann, R. Nakamura, M. Kirby, and A.J. Barrett Molecular and flow cytometric characterization of the CD4 and CD8 T-cell repertoire in patients with myelodysplastic syndrome Br J Haematol 119 2002 97 105
24. F. Bertolini, W. Mingrone, A. Alietti, P.F. Ferrucci, E. Cocorocchio, and F. Peccatori Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and surrogate angiogenesis markers Ann Oncol 12 2001 987 990
25. A. Janowska-Wieczorek, L.A. Marquez, A. Matsuzaki, H.R. Hashmi, L.M. Larratt, and L.M. Boshkov Expression of matrix metalloproteinases (MMP-2 and -9) and tissue inhibitors of metalloproteinases (TIMP-1 and -2) in acute myelogenous leukaemia blasts: comparison with normal bone marrow cells Br J Haematol 105 1999 402 411